Evidence map›Paper›PMID 30845903›Full record

Observational studyCurrent aging science2019

Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases.

Alon Seifan, Christine A Ganzer, Krista Ryon, Michael Lin, Rahman Mahmudur, Henriquez Adolfo, Cindy Shih, Alan R Jacobs, Molly Greenwald, Richard S Isaacson

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Current aging science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Intrinsic capacity in Lewy body dementia: a review.The Journal of frailty & aging · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Hearing and dementia: from ears to brain.Brain : a journal of neurology · 2021
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Alon SeifanNeuro Well Free, Medicine, Fort Lauderdale, Florida, United States.
Christine A GanzerHunter College, Nursing, New York, United States.
Krista RyonNova Southeastern, Medicine, Fort Lauderdale, Florida, United States.
Michael LinNova Southeastern, Medicine, Fort Lauderdale, Florida, United States.
Rahman MahmudurNeuro Well Free, Medicine, Fort Lauderdale, Florida, United States.
Henriquez AdolfoNeuro Well Free, Medicine, Fort Lauderdale, Florida, United States.
Cindy ShihDepartment of Neurology, Weill Cornell Medicine, New York, United States.
Alan R JacobsPrivate Practice, Medicine, New York, United States.
Molly GreenwaldPrivate Practice, Medicine, New York, United States.
Richard S IsaacsonDepartment of Neurology, Weill Cornell Medicine, New York, United States.
The Neuro Well · USCornell University · USNova Southeastern University · USHunter College · US

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384
6 · The paper itself

Abstract

backgroundProdromal Neurodegenerative Disease (ND) due to tauopathies such as Alzheimer's Disease (AD) and Synucleinopathies (SN) such as Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB) present subtly. Although ND are considered cognitive disorders, in fact ND present with behavioral and even medical symptomatology years to decades prior to the onset of cognitive changes. Recognizing prodromal ND syndromes is a public health priority because ND is common, disabling and expensive. Diagnosing prodromal ND in real world clinical settings is challenging because ND of the same pathology can present with different symptoms in different people. Individual variability in nature and variability in nurture across the life course influence how ND pathology manifests clinically. The objective of this study was to describe how non-cognitive symptoms from behavioral, medical, neurological and psychiatric domains cluster in prodromal and early stages of ND.

methodsThis was an observational study of patients receiving routine clinical care for memory disorders. All patients receiving a standardized evaluation including complete neurological history and examination and standardized brief neuropsychological testing. A Principal Component Analysis (PCA) considering emotion, motor, sensory and sleep factors was performed on the entire sample of patients in order to identify co-occurring symptom clusters. All patients received a consensus diagnosis adjudicated by at least two dementia experts. Patients were grouped into Cognitively Normal, Detectable Cognitive Impairment, and Mild Cognitive Impairment categories due to AD and/or PD/LBD or NOS pathology. Symptom cluster scores were compared between clinical diagnostic groups.

resultsIn this study 165 patients completed baseline neuropsychological testing and reported subjective measures of non-cognitive symptoms. Four syndrome specific symptom factors emerged and eight non-specific symptom factors. Symptoms of personality changes, paranoia, hallucinations, cravings, agitation, and changes in appetite grouped together into a cluster consistent with an "SN Non-motor Phenotype". Appetite, walking, balance, hearing, increased falls, and dandruff grouped together into a cluster consistent with an "SN Motor Phenotype". The Prodromal AD phenotype included symptoms of anxiety, irritability, apathy, sleep disturbance and social isolation. The fourth factor included symptoms of increased sweating, twitching, and tremor grouped into a cluster consistent with an Autonomic phenotype.

conclusionNon-cognitive features can be reliably measured by self-report in busy clinical settings. Such measurement can be useful in distinguishing patients with different etiologies of ND. Better characterization of unique, prodromal, non-cognitive ND trajectories could improve public health efforts to modify the course of ND for all patients at risk.

Indexed as

AdultAgedAged, 80 and overAlzheimer DiseaseCognitive DysfunctionEarly DiagnosisFemaleHumansLewy Body DiseaseMaleMiddle AgedNeurodegenerative DiseasesNeuropsychological TestsParkinson DiseasePhenotypeProdromal SymptomsAlzheimer’s diseasedementiamild cognitive impairmentneurodegenerativeNon-cognitiveself-report.

Identifiers

PMID30845903
PMCPMC6635426
OpenAlexW2911799491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.